Silvio E Inzucchi

48PUBLICATIONS
174CO-AUTHORS
HaematologyBehavioural epidemiologyCardiology (incl. cardiovascular diseases)Molecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (48)

|Jul 21, 2026
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?

|Sep 23, 2025
Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.

Rodica Pop-Busui, Samuel P Rosin, Nicole M Butera

|Aug 30, 2025
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.

David D Berg, Siddharth M Patel, Paul M Haller

|Mar 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.

Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui

|Mar 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Nikolaus Marx, John E Deanfield, Johannes F E Mann

|Oct 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Senthil Selvaraj, Shachi Patel, Andrew J Sauer

Pageof 8

Frequent Collaborators

15 joint publications

Mikhail N Kosiborod

12 joint publications

John J V McMurray

9 joint publications

Muthiah Vaduganathan

9 joint publications

Pardeep S Jhund